help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chiou, S.
Right arrow Articles by Vesely, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chiou, S.
Right arrow Articles by Vesely, D. L.

Endocrinology, Vol 136, 2033-2039, Copyright © 1995 by Endocrine Society


ARTICLES

Kaliuretic peptide: the most potent inhibitor of Na(+)-K+ ATPase of the atrial natriuretic peptides

S Chiou and DL Vesely
Department of Medicine, University of South Florida Health Sciences Center, Tampa, USA.

The present investigation was designed to determine whether atrial natriuretic peptides consisting of amino acids 1-30 (i.e. long-acting natriuretic peptide), 31-67 (vessel dilator), 79-98 (kaliuretic peptide), and 99-126 [atrial natriuretic factor (ANF)] of the 126 amino acid ANF prohormone inhibit sodium-potassium-ATPase as part of their mechanism(s) of action for producing a natriuresis and/or kaliuresis. Kaliuretic peptide, long-acting natriuretic peptide, vessel dilator and ANF at their 10(-11) M concentrations inhibited Na(+)-K(+)-ATPase 39.5%, 27.8%, 19.2%, and 4% respectively, in bovine renal medulla, whereas their inhibition in renal cortical membranes was 37.5%, 27.5%, 20%, and 0%, respectively. Ouabain (0.5 mM) inhibited kidney medullary Na(+)-K(+)-ATPase 45% and in the cortex, 38%. There was no additive effect of any of these peptides with ouabain suggesting that they are interacting with the same site on the Na(+)-K(+)-ATPase as ouabain. To help elucidate the mechanism of these peptides' interaction with Na(+)- K(+)-ATPase, naproxen (0.5 mM), an inhibitor of prostaglandin synthesis, and direct measurement of prostaglandin E2 by RIA were used. Naproxen completely blocked the inhibition of Na(+)-K(+)-ATPase by kaliuretic peptide, long-acting natriuretic peptide, and vessel dilator suggesting that their inhibition of Na(+)-K(+)-ATPase in both the kidney medulla and cortex are mediated by prostaglandins. Direct measurement of prostaglandin E2 revealed that kaliuretic peptide > long- acting natriuretic peptide > vessel dilator increased prostaglandin E2 synthesis, whereas ANF did not have any effect. Of interest, angiotensin II and ouabain inhibition of Na(+)-K(+)-ATPase were also completely blocked by naproxen.


This article has been cited by other articles:


Home page
HypertensionHome page
O. V. Fedorova, N. I. Agalakova, C. H. Morrell, E. G. Lakatta, and A. Y. Bagrov
ANP Differentially Modulates Marinobufagenin-Induced Sodium Pump Inhibition in Kidney and Aorta
Hypertension, December 1, 2006; 48(6): 1160 - 1168.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
H. Patel, J. R. Dietz, A. Owen, G. S. Miguel, M. T. McCormick, D. D. Schocken, and D. L. Vesely
Combined Treatment with Vessel Dilator and Kaliuretic Hormone in Persons with Congestive Heart Failure
Experimental Biology and Medicine, June 1, 2004; 229(6): 521 - 527.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
D. L. Vesely
Natriuretic peptides and acute renal failure
Am J Physiol Renal Physiol, August 1, 2003; 285(2): F167 - F177.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. L Vesely
Atrial natriuretic peptides in pathophysiological diseases
Cardiovasc Res, September 1, 2001; 51(4): 647 - 658.
[Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
J. R. Dietz, D. Y. Scott, C. S. Landon, and S. J. Nazian
Evidence supporting a physiological role for proANP-(1-30) in the regulation of renal excretion
Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2001; 280(5): R1510 - R1517.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
L. C. Clark, H. Farghaly, S. R. Saba, and D. L. Vesely
Amelioration with vessel dilator of acute tubular necrosis and renal failure established for 2 days
Am J Physiol Heart Circ Physiol, May 1, 2000; 278(5): H1555 - H1564.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. Zellner, A. A. Protter, E. Ko, M. R. Pothireddy, T. DeMarco, S. J. Hutchison, T. M. Chou, K. Chatterjee, and K. Sudhir
Coronary vasodilator effects of BNP: mechanisms of action in coronary conductance and resistance arteries
Am J Physiol Heart Circ Physiol, March 1, 1999; 276(3): H1049 - H1057.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. L. Vesely, J. R. Dietz, J. R. Parks, M. Baig, M. T. McCormick, G. Cintron, and D. D. Schocken
Vessel Dilator Enhances Sodium and Water Excretion and Has Beneficial Hemodynamic Effects in Persons With Congestive Heart Failure
Circulation, July 28, 1998; 98(4): 323 - 329.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
B. H. Ackerman, R. M. Overton, M. T. McCormick, D. D. Schocken, and D. L. Vesely
Disposition of Vessel Dilator and Long-Acting Natriuretic Peptide in Healthy Humans after a One-Hour Infusion
J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 603 - 608.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1995 by The Endocrine Society